leisure time -WSS

leisure time

author：focus 2025-10-01 00:47:52 - browse：68879

Zepbound, a injectable drug on a gradient background of dark purple and green — biotech coverage from STAT — Illustration: STAT; Source: Eli Lilly/AP

A California biotech developing a combination therapy with the obesity drug Zepbound has raised a $170 million Series D round.

The company, BioAge, raised money from more than a dozen investors. Sofinnova Investments led the round, which also included Eli Lilly and Amgen’s venture arms and previous investor Andreessen Horowitz.

BioAge’s primary focus is in developing medications that boost a person’s healthspan, or the number of healthy years a person lives. The company has drugs in development for neuroinflammation and brain aging. But the majority of the Series D proceeds will be used to develop the company’s lead drug candidate azelaprag, which is being tested in combination with Zepbound. That drug program is what grabbed Sofinnova’s attention, according to managing partner Jim Healy, who recently became chairman of BioAge’s board.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： New air purifier tech could be key to improving indoor air quality
Next article： J&J to emphasize cancer drugs, stop much of its vaccine research

focus

WSS

Disappointing trial forces Pfizer to pivot on obesity medicine plans

After affirmative action ruling, medical educators look to 'holistic review'

Rep. Raul Ruiz on the physician shortage and more

Dobbs anniversary: the lost opportunity of abortion as health care

Will the market for weight loss drugs really reach $100 billion?

State Dept. review finds Biden bears some blame for Afghanistan failures

Wikipedia

leisure time

focus

DIEP, the 'gold standard' of breast reconstruction, is under threat

Peter Hotez and the public health issue of online harassment

Guidelines to prevent youth baseball injuries need more muscle

Disappointing trial forces Pfizer to pivot on obesity medicine plans

George Santos makes 1st court appearance after pleading not guilty to 13 counts

DIEP, the 'gold standard' of breast reconstruction, is under threat

How to save PrEP access — and even expand it

What don’t we know about an Alzheimer’s drug side effect?

Food as medicine: CMS rules hamper 'prescribing' of fruits, veggies

Disappointing trial forces Pfizer to pivot on obesity medicine plans

focus

Despite FDA concern, risk that CAR

Trump demands the U.S. pay no more for drugs than other countries … again

UnitedHealth has 90,000 doctors — 10% of all physicians in U.S.

UnitedHealth’s Optum accused of antitrust violations in California

Fetal surgery at risk from Dobbs and new abortion restrictions

FDA investigates CAR

Wikipedia

focus

leisure time

focus